Prophylactic Treatment Lowers Skin Toxicity in NSCLC Patients on Amivantamab + Lazertinib

While the combination of amivantamab plus lazertinib for first-line NSCLC treatment offers a significant survival benefit, it also comes with an increased risk of dermatologic adverse events. In this interview, Nicolas Girard, Professor and Head of Thoracic Oncology at Institut Curie in Paris, discusses practical strategies to manage these side effects and enhance patient experience.